Flaka Radoniqi is a Principal Scientist and a group lead at Amgen within Pivotal Drug Substance Biologics. After completing her graduate studies at Keck Graduate Institute, Flaka joined Amgen in 2018 supporting various programs throughout their life cycle management and late-phase stages. Flaka has contributed to various modalities and process modes, enabling tech transfer, commercial manufacturing, and regulatory filings for critical programs. Flaka has also had a significant role in technology advancements at Amgen, including harvest and continuous manufacturing development. Outside of pipeline contributions, Flaka is involved in initiatives for cross functional process efficiency improvements and agile ways.